The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.

Vasorelaxing peptides could offer a promising therapeutic strategy for reducing the neurological deficits caused by subarachnoid hemorrhage-induced cerebral blood vessel constriction.

Voluntary data sharing across a region’s health systems and ambulatory care practices is important for measuring and improving health care quality and safety, Vanderbilt researchers report.

Racial disparities in hypertension risk are due in part to genetic differences between ancestries, Vanderbilt investigators find in a study of participants in the Million Veteran Program.

A compound that increases lifespan in yeast is offering clues to pharmacological approaches that might slow the aging process and improve health.

Aviv Regev, PhD, an internationally known computational biologist and executive vice president of Genentech Research and Early Development (gRED), is the recipient of the 2021 Vanderbilt Prize in Biomedical Science, officials at Vanderbilt University Medical Center announced this week.